6 suspended. 6 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Suspended 6 |
| Phase 1 | 5 | Suspended 5 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-04 | 2026-10-30 |
| External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Extramedullary Disease in Multiple Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Suspended | City of Hope Medical Center | 20 | 2025-08-29 | 2026-10-07 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Iberdomide, Belantamab Mafodotin, Dexamethasone - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Alliance for Clinical Trials in Oncology | 88 | 2025-04-23 | 2026-10-02 |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Suspended | National Cancer Institute (NCI) | 84 | 2024-08-27 | 2026-10-19 |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib, Iberdomide, Oral Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Hackensack Meridian Health | 66 | 2022-05-13 | 2026-07-13 |
| Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma NEXI-002 T Cells - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | NexImmune Inc. | 9 | 2020-08-17 | 2024-01-16 |
Blood Protein Disorders (6) · Cardiovascular Diseases (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Hemorrhagic Disorders (6) · Hemostatic Disorders (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Plasma Cell (6) · Paraproteinemias (6) · Vascular Diseases (6)
Magnetic Resonance Spectroscopy (3) · iberdomide (3) · Biopsy (2) · Dexamethasone (2) · Specimen Handling (2) · Congresses as Topic (1) · Image-Guided Biopsy (1) · Radiation (1) · Remote Patient Monitoring (1) · Sirolimus (1) · X-Rays (1) · belantamab mafodotin (1) · carfilzomib (1) · mirdametinib (1) · talquetamab (1)
National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Hackensack Meridian Health (1) · NexImmune Inc. (1)
United States (6)
Elizabeth M Hill, M.D. (1) · Kristi Jones (1) · Noa Biran, MD (1) · Sascha A Tuchman (1) · Scott R Goldsmith (1)
P30CA033572 (1), U10CA180821 (1)